ArticleExperimental and therapeutic medicine2026
Effect of rivaroxaban on DNA damage in an ischemia-reperfusion model: Evaluation of 8-OHdG levels.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia-reperfusion (I/R) injury is a notable cause of tissue damage, particularly in patients with peripheral artery disease. Rivaroxaban is a novel oral anticoagulant that can reduce cardiovascular events. However, its potential antioxidant properties remain poorly understood. Therefore, the present study aimed to investigate the effect of rivaroxaban on oxidative DNA injury in a rat model of I/R injury by measuring 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels, a key biomarker of oxidative DNA injury. A total of 21 female Wistar albino rats were randomly divided into three groups, namely the sham, control (I/R) and rivaroxaban treatment (3 mg/kg/day) groups. Following treatment for 10 days, hind limb ischemia was induced in rats for 1 h, followed by reperfusion for 2 h. Subsequently, blood and skeletal muscle samples were collected and analyzed for oxidative stress markers, including 8-OHdG, glutathione (GSH), oxidized GSH and malondialdehyde (MDA), using ELISA and high-performance liquid chromatography. The results demonstrated that compared with those in the sham group, rats in the control group exhibited significantly elevated 8-OHdG, GSSG and MDA levels, coupled with decreased GSH levels. By contrast, treatment with rivaroxaban notably reversed the elevated 8-OHdG and MDA levels whilst restoring GSH levels compared with those in the control group, indicating an improved oxidative status. Overall, these findings suggested that in addition to its established anticoagulant properties, rivaroxaban can also protect against I/R-induced oxidative DNA injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.